Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Zyneyro’s CEO on the collaboration with CombiGene

At the beginning of the year, CombiGene and Zyneyro entered into a collaboration for the development of new treatments for severe chronic pain conditions. The pain programme COZY consists of a peptide treatment and a gene therapy treatment. The gene therapy is reserved for patients where the possibilities for spontaneous reduction of the pain are considered excluded or unlikely. Zyneyro’s CEO Peter Horn Møller talks with BioStock about the collaboration and overall vision.Read the full interview with Peter Horn Møller at biostock.se: https://www.biostock.se/en/2023/05/zyneyros-ceo-on-the-

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING IN INCOAX NETWORKS AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.    The shareholders of InCoax Network AB (publ), Reg. No. 556794-1363, are hereby invited to attend the annual shareholders’ meeting on Thursday 15 June 2023 09.00.Right to participate and notification  Shareholders wishing to participate in the annual shareholders’ meeting must:  · partly be listed in the company’s share register kept by Euroclear Sweden AB as of Wednesday 7 June 2023; and  · partly have given a

HC Andersen Capital Events 17/05: Meet the top management in Audientes & Scandinavian Medical Solutions

HC Andersen Capital is hosting digital events where you can meet and ask questions directly to the top management. It is free for all to attend.Audientes - Business updateAudientes updated its financial calendar on May 16th and this event will therefore be a business update. Audientes will publish its full-year report on 13 June 2023. Audientes has already announced their Q4 2022 results and decided not to announce any guidance for 2023 due to the uncertainty around the size of funding in the short-term, as well as in the medium term. Furthermore, the company has informed the market

Epiroc to purchase key assets in Australian mining equipment manufacturer

Stockholm, Sweden: Epiroc, a leading productivity and sustainability partner for the mining and infrastructure industries, has agreed to purchase the key assets of Schramm Australia, a leading manufacturer of products for reverse circulation (RC) drilling.Since February 2023, Schramm Australia, based in Perth, has been in voluntary administration, and Epiroc will now continue the business to the benefit of the customers. The assets include intellectual property as well as two production facilities near Perth and two service centers located in Queensland and South Australia. Schramm

The subscription period in Carbiotix AB´s issue of units starts today

Today, the 17th of May 2023, the subscription period in Carbiotix AB’s ("Carbiotix" or "Company") issue of units consisting of shares and free warrants of series TO2 (”TO 2”), with preferential rights for the Company's existing shareholders begins. The subscription period runs until the 2nd of June 2023. The issue volume initially amounts to a maximum of approximately SEK 12 million before transaction costs (the "Rights Issue"). Upon full subscription of the Rights Issue and full utilization of issued TO 2 at the highest subscription price, the Company may receive an additional approximately

Klimator AB (publ) Interim Report 1, January – March 2023

First quarter January 1 – March 31, 2023 Group · Operating income amounted to SEK 7,520K (SEK 5,594K) · Operating profit amounted to SEK -5,567K (SEK -6,052K) · Net profit after income taxes amounted to SEK -5,825K (SEK -6,135K) · Cash flow from current operations amounted to SEK -6 425K (-807K) · Number of shares as of March 31st amounted to 28 824 751 (13 400 000) · Net profit per share after income taxes amounted to SEK -0.20 (SEK -0.46)       (Amounts within parentheses refer to the corresponding figures for the same period the prior year) Material events

Scandinavian Enviro Systems (publ) publishes Annual Report 2022

Scandinavian Enviro Systems’ Annual Report for 2022 is as of today, Wednesday May 17 2023, available in Swedish on the company’s website https://envirosystems.se/investor/reports-presentations/.For further information, please contact:Thomas Sörensson, CEO Enviro, +46 (0)735-10 53 43, thomas.sorensson@envirosystems.seAlf Blomqvist, Chairman of the Board Enviro, +46 (0)733-14 97 00, alf@blomqvistunlimited.com Mangold Fondkommission AB is Enviro’s Certified Adviser on Nasdaq First North Growth Market Stockholm. Scandinavian Enviro Systems ABFrihamnen 16B, SE-417 70 Gothenburginfo@

The subscription price for the warrants of series TO3 in Wyld Networks AB has been determined to SEK 7.31 and the subscription period starts today, May 17, 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. In August 2021, Wyld Networks AB (“Wyld Networks” or the “Company”) entered a loan agreement. In connection with the procured loan Wyld Networks issued in total 2,275,000 warrants

Year-end report 1 April 2022 - 31 March 2023

Fourth quarter (1 January - 31 March 2023) · Net sales increased by 34 percent and amounted to SEK 5,267 million (3,916). · Operating profit before amortisation of intangible non-current assets (EBITA) increased by 47 percent and amounted to SEK 758 million (517) corresponding to an EBITA margin of 14.4 percent (13.2).  · Operating profit increased by 51 percent and amounted to SEK 660 million (436) corresponding to an operating margin of 12.5 percent (11.1). · Profit after tax increased by 42 percent and amounted to SEK 461 million (325) and earnings per share before dilution

Nordea cancels repurchased shares

Nordea Bank AbpStock exchange release – Total number of voting rights and capital17 May 2023 at 9.15 EET Nordea has today cancelled 6,558,616 treasury shares in line with the decision by the Board of Directors. The shares were held for capital optimisation purposes and acquired through share buy-backs. The cancellation brings the total number of shares in Nordea to 3,598,245,264. The total number of votes attached to the shares is 3,598,245,264. The cancellation of the shares was registered with the Finnish Trade Register on 17 May 2023. The company holds 1,265,819 treasury

Q1 2023 - Growth continues in the consulting industry

The trend of strong growth figures for Swedish and Finnish listed consulting firms continues during the first quarter. However, the growth is slowing down, and considering the high inflation, it is no longer particularly robust. The demand is generally good but highly differentiated.  The EBIT-margins are almost on par with last year. This is shown in the new infographic of the quarterly reports of the publicly listed consulting firms in Sweden and Finland.https://cinode.com/en/business-en/– During Q1, we observe a more differentiated consulting market. Companies with exposure to energy,

CS MEDICA A/S: Publication of Q2 2022/2023 report & invitation to live-streamed conference on May 24, at 10 AM CET

CS MEDICA (”CS MEDICA” or the ”Company”) hereby publishes its Q2 report for the period January – Marts 2023. Highlights of the Quarter will be presented at a live-streamed conference on Wednesday, May 24 at 10 AM CET. The Q2 report is available as an attached document to this press release and on the Company's website (www.cs-medica.com). Below is a summary of the report.Financial highlights for Q2 2022/2023 · In this second quarter of 2022/2023 (January – March 2023), CS MEDICA received orders corresponding to mDKK 1.9, which together with the orders from Q1, mDKK 1.1, total mDKK 3.0,

Flemingsberg Block Party aims to create a sense of community and pride in the ongoing urban development

On 15-17 June, Flemingsberg Block Party will take place in the centre of Flemingsberg, featuring music, art, dance and numerous other activities. The festival is being organised by the urban developer Fabege, Huddinge Municipality and Södertörn University, together with local associations and festival organisers.The aim of the initiative is to strengthen Flemingsberg as a meeting place for knowledge and creativity and to create collaboration and pride in the development of Flemingsberg. - Flemingsberg is one of Sweden’s biggest and also most important development projects. The long-term

Askel Healthcare has appointed globally renowned orthopedic surgeons and sports medicine specialists to its new Clinical Advisory Board to drive change in the treatment of knee cartilage repair

Askel Healthcare, a Finnish medical technology company offering a new method for the treatment of knee cartilage defects, has established a Clinical Advisory Board (CAB) representing globally renowned orthopedic surgeons and sports medicine specialists in knee cartilage repair. The newly appointed CAB will have an instrumental advisory role in gathering of high-level clinical evidence of the broad benefits of the COPLA[®] implant and its successful commercialization. COPLA[®] is a biodegradable implant for surgical treatment of cartilage damage in the knee. In the first phase of

Bricknode interim report: January – March 2023

Bricknode has today published its interim report for the period January – March 2023. The report is attached to this press release and is available on the Bricknode website .Q1 2023 in brief · Entered purchase agreement with Huddlestock Fintech AS ("Huddlestock") regarding the transfer of all operational assets of Bricknode for 41,138,911 consideration shares in Huddlestock · Net revenue increased by 7% to 5,002 (4,671) TSEK · Net revenue retention rate 96% (107%) · Earnings per share amounted to

Mycronic receives order for a Prexision 8 Evo and a Prexision Lite 8 Evo

Mycronic AB (publ) has received an order for a Prexision 8 Evo and a Prexision Lite 8 Evo from an existing customer in Asia. The order value is in the range of USD 31-34 million. Delivery of the Prexision 8 Evo is planned for the first quarter of 2025, while the Prexision Lite 8 Evo is planned for delivery during the fourth quarter of 2024.Prexision 8 Evo meets the market’s requirements regarding complex patterns for display photomasks. Prexision Lite 8 Evo is designed to meet the requirements for cost-efficient production of photomasks for displays.   “The order for a Prexision 8 Evo

Metacon publishes interim report for Q1 2023

The potential and role of hydrogen in the energy and fuel transition is becoming clearer and clearer every day. Metacon is emerging as a supplier of powerful solutions for fossil-free hydrogen to several different needs and customer groups. Christer Wikner, President and CEO For the full CEO-comment, see the Interim report in its entirety. Quarter for the Group Jan–Mar 2023 · Revenues amounted to SEK 16.3 (12.6) million. · Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to SEK -12.7  (-5.8) million. · Operating profit (EBIT) amounted to

Volvo Group Mobility Transformation Forum calls for collaboration to speed up Europe's fossil-free future

May 17, 2023 - Volvo Group is calling for increased dialogue between policymakers and the industry around the future of mobility at its annual Mobility Transformation Forum in Brussels on May 23, which will be streamed live on LinkedIn . The event will showcase Volvo Group’s continued investment in fossil-free propulsion technologies, services, and business solutions, and highlight the need for investment in infrastructure and charging capabilities across Europe.Alongside panel discussions and talks, Volvo’s battery electric,

Asetek A/S – Admission to trading and official listing on Nasdaq Copenhagen A/S

Aalborg, 17 May 2023. NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. On 18 April 2023, Nasdaq Copenhagen A/S ("Nasdaq Copenhagen") provided their conditional approval for the admission to trading and official listing of Asetek A/S' (the "Company") shares (in the form of share entitlements) on Nasdaq Copenhagen under the symbol "ASTK". As per the approval, and due to the satisfaction of the conditions contained therein, trading

Acroud publishes interim report Jan-Mar 2023: A quarter with substantial NDC growth

Financial highlights during first quarter 2023 · Revenue amounted to EUR 9 300 (7 003) thousand, corresponding to a growth of 33% and an organic growth of -21.7%. · EBITDA amounted to EUR 2 114 (2 248) thousand, decreased by 6% year-on-year. · Adjusted EBITDA (before items affecting comparability) was EUR 2 141 (1 781) thousand increasing by 20% year-on-year. · Profit after tax was EUR -67 (1 184) thousand. Adjusted profit after tax (before items affecting comparability and currency effects) was EUR -181 (551) thousand. · Earnings per share after dilution amounted to EUR -0.

IRRAS AB publishes Interim Report for the period January to March 2023

” Encouraging start to 2023 for IRRAS as our total revenue of MSEK 11.2 marked the highest quarterly revenue total in the company’s history.” ” Commercial activity and IRRAflow utilization continue to increase in the US market.  During Q1, the US market accounted for 83% of our total revenue, and 95% of that US revenue was generated by reorders from existing customers.” Will Martin, CEO of IRRASFirst quarter, January – March 2023 · Net revenue amounted to SEK 11.2 million (8.6). · Operating loss (EBIT) amounted to SEK -59.2 million (-33.7). · Loss after tax amounted to SEK -

Tagrisso plus chemo improved PFS in lung cancer

17 May 2023 Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutatedadvanced lung cancer in FLAURA2 Phase III trial Results support potential for a new treatment option that builds onthe benefit of first-line standard of care Tagrisso monotherapy Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca's Tagrisso (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to Tagrisso

Pharmacolog: Interim report January - March 2023

Press release: Uppsala, May 17, 2023. Pharmacolog i Uppsala AB’s (publ) interim report for the period January – March is now available on the company’s website https://pharmacolog.com/investor-relations-2/financial-reports/ (Swedish only)Första kvartalet 1 januari – 31 mars 2023 · Koncernens nettoomsättning för det första kvartalet uppgick till 4 729 (2 021) KSEK. · Rörelseresultatet för kvartalet uppgick till -4 299 (-4 318) KSEK. · Nettoresultat per aktie före och efter utspädning var för kvartalet -0,22 (-0,28) SEK. Väsentliga händelser under perioden 1 januari – 31 mars

Orthex Corporation: Interim report January-March 2023

Orthex Corporation, Stock exchange release, 17 May 2023 at 9.00 a.m. EESTProfitability improved. Strong sales growth in European strategic markets, consumer uncertainty hampered sales in the Nordics. This release is a summary of Orthex Corporation’s Interim report for January–March 2023. The complete report is attached to this release as a pdf-file. It is also available on Orthex’s website at https://investors.orthexgroup.com/.January–March 2023 · Invoiced sales decreased by 1.3% and totalled EUR 21.2 million (21.5) · Net sales decreased by 0.5% to EUR 20.5 million (20.6) ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top